Catalent Past Earnings Performance
Past criteria checks 0/6
Catalent's earnings have been declining at an average annual rate of -31.7%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 13.1% per year.
Key information
-31.7%
Earnings growth rate
-32.0%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 13.1% |
Return on equity | -35.3% |
Net Margin | -31.8% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Catalent makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 4,098 | -1,302 | 853 | 0 |
30 Sep 23 | 4,223 | -1,015 | 829 | 0 |
30 Jun 23 | 4,263 | -256 | 829 | 0 |
31 Mar 23 | 4,495 | 21 | 850 | 0 |
31 Dec 22 | 4,731 | 389 | 866 | 0 |
30 Sep 22 | 4,799 | 399 | 867 | 0 |
30 Jun 22 | 4,802 | 483 | 844 | 0 |
31 Mar 22 | 4,703 | 485 | 803 | 0 |
31 Dec 21 | 4,483 | 561 | 768 | 0 |
30 Sep 21 | 4,177 | 544 | 706 | 0 |
30 Jun 21 | 3,998 | 529 | 687 | 0 |
31 Mar 21 | 3,757 | 494 | 658 | 0 |
31 Dec 20 | 3,465 | 289 | 623 | 0 |
30 Sep 20 | 3,275 | 250 | 598 | 0 |
30 Jun 20 | 3,094 | 173 | 577 | 0 |
31 Mar 20 | 2,872 | 104 | 562 | 1 |
31 Dec 19 | 2,729 | 124 | 554 | 2 |
30 Sep 19 | 2,631 | 138 | 535 | 3 |
30 Jun 19 | 2,518 | 132 | 512 | 0 |
31 Mar 19 | 2,478 | 149 | 489 | 4 |
31 Dec 18 | 2,488 | 136 | 475 | 5 |
30 Sep 18 | 2,471 | 65 | 466 | 5 |
30 Jun 18 | 2,463 | 84 | 459 | 6 |
31 Mar 18 | 2,395 | 63 | 430 | 7 |
31 Dec 17 | 2,300 | 70 | 413 | 7 |
30 Sep 17 | 2,177 | 109 | 396 | 7 |
30 Jun 17 | 2,075 | 110 | 396 | 7 |
31 Mar 17 | 1,991 | 106 | 373 | 7 |
31 Dec 16 | 1,896 | 91 | 365 | 7 |
30 Sep 16 | 1,867 | 104 | 362 | 8 |
30 Jun 16 | 1,848 | 112 | 351 | 8 |
31 Mar 16 | 1,826 | 207 | 346 | 10 |
31 Dec 15 | 1,835 | 228 | 333 | 10 |
30 Sep 15 | 1,836 | 244 | 327 | 11 |
30 Jun 15 | 1,831 | 212 | 325 | 12 |
31 Mar 15 | 1,840 | 86 | 315 | 14 |
31 Dec 14 | 1,847 | 62 | 320 | 15 |
30 Sep 14 | 1,832 | -3 | 318 | 17 |
30 Jun 14 | 1,828 | 19 | 317 | 18 |
31 Mar 14 | 1,813 | 2 | 328 | 17 |
31 Dec 13 | 1,807 | -20 | 326 | 16 |
30 Sep 13 | 1,803 | -29 | 325 | 15 |
30 Jun 13 | 1,800 | -51 | 326 | 15 |
Quality Earnings: 0C8 is currently unprofitable.
Growing Profit Margin: 0C8 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0C8 is unprofitable, and losses have increased over the past 5 years at a rate of 31.7% per year.
Accelerating Growth: Unable to compare 0C8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0C8 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: 0C8 has a negative Return on Equity (-35.31%), as it is currently unprofitable.